Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1

Experimental Cell Research

Volumn 317, Issue 4, 2011, Pages 504-512

  Yi, Wei ^a,b   Holmlund, Camilla ^a   Nilsson, Jonas ^a   Inui, Shigeki ^c   Lei, Ting ^b   Itami, Satoshi ^c   Henriksson, Roger ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ADAM17; Cell proliferation; EGFR; LRIG1; Shedding; TACE

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAINS 1; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 78651424398     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.11.005     Document Type: Article

References (29)

1. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature 2001, 411:355-365.
2. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
3. Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004, 23:3270-3281.
4. Laederich M.B., Funes-Duran M., Yen L., Ingalla E., Wu X., Carraway K.L., Sweeney C. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J. Biol. Chem. 2004, 279:47050-47056.
5. Shattuck D.L., Miller J.K., Laederich M., Funes M., Petersen H., Carraway K.L., Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol. Cell. Biol. 2007, 27:1934-1946.
6. Ledda F., Bieraugel O., Fard S.S., Vilar M., Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J. Neurosci. 2008, 28:39-49.
7. Hedman H., Henriksson R. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer?. Eur. J. Cancer 2007, 43:676-682.
8. Jensen K.B., Watt F.M. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11958-11963.
9. Jensen K.B., Collins C.A., Nascimento E., Tan D.W., Frye M., Itami S., Watt F.M. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 2009, 4:427-439.
10. Suzuki Y., Miura H., Tanemura A., Kobayashi K., Kondoh G., Sano S., Ozawa K., Inui S., Nakata A., Takagi T., Tohyama M., Yoshikawa K., Itami S. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett. 2002, 521:67-71.
11. Karlsson T., Mark E.B., Henriksson R., Hedman H. Redistribution of LRIG proteins in psoriasis. J. Invest. Dermatol. 2008, 128:1192-1195.
12. Tanemura A., Nagasawa T., Inui S., Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol. Surg. 2005, 31:423-430.
13. Lindström A.K., Ekman K., Stendahl U., Tot T., Henriksson R., Hedman H., Hellberg D. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int. J. Gynecol. Cancer 2008, 18:312-317.
14. Jensen K.B., Jones J., Watt F.M. A stem cell gene expression profile of human squamous cell carcinomas. Cancer Lett. 2008, 272:23-31.
15. Thomasson M., Hedman H., Guo D., Ljungberg B., Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br. J. Cancer 2003, 89:1285-1289.
16. Miller J.K., Shattuck D.L., Ingalla E.Q., Yen L., Borowsky A.D., Young L.J., Cardiff R.D., Carraway K.L., Sweeney C. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res. 2008, 68:8286-8294.
17. Suzuki Y., Sato N., Tohyama M., Wanaka A., Takagi T. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J. Biol. Chem. 1996, 271:22522-22527.
18. Nilsson J., Vallbo C., Guo D., Golovleva I., Hallberg B., Henriksson R., Hedman H. Cloning, characterization, and expression of human LIG1. Biochem. Biophys. Res. Commun. 2001, 284:1155-1161.
19. Holmlund C., Nilsson J., Guo D., Starefeldt A., Golovleva I., Henriksson R., Hedman H. Characterization and tissue-specific expression of human LRIG2. Gene 2004, 332:35-43.
20. Guo D., Holmlund C., Henriksson R., Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues, and a homolog in Ascidiacea. Genomics 2004, 84:157-165.
21. Goldoni S., Iozzo R.A., Kay P., Campbell S., McQuillan A., Agnew C., Zhu J.X., Keene D.R., Reed C.C., Iozzo R.V. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007, 26:368-381.
22. Nilsson J., Starefeldt A., Henriksson R., Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res. 2003, 312:65-71.
23. Gordon J.A. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Meth. Enzymol. 1991, 201:477-482.
24. Stutz M.A., Shattuck D.L., Laederich M.B., Carraway K.L., Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008, 27:5741-5752.
25. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
26. Mochizuki S., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98:621-628.
27. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 2009, 15:1140-1144.
28. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., Hartmann D., Saftig P., Blobel C.P. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 2004, 164:769-779.
29. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.